Physician profile
Corey D Hunt
NPI 1902997745
$3,387.47
in general payments reported to CMS, 2019-2025
34 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $608 · 2021: $1,001 · 2022: $643 · 2023: $363 · 2024: $280 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $445.24 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $436.10 | 2021-2025 | |
| Novo Nordisk INC | $399.57 | 2020-2025 | Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $298.59 | 2020-2024 | Nexletol |
| Lilly USA, LLC | $213.76 | 2019-2024 | Jardiance, Mounjaro |
| Merck Sharp & Dohme LLC | $182.85 | 2019-2023 | Verquvo, Vaxneuvance, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $175.59 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.63 | 2020-2023 | Xifaxan, Trulance |
| Supernus Pharmaceuticals, INC. | $127.85 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.77 | 2021-2024 | |
| Dexcom, INC. | $106.90 | 2021-2022 | |
| Exact Sciences Corporation | $99.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $84.05 | 2019-2021 | |
| Daiichi Sankyo INC. | $69.30 | 2020-2022 | |
| Amgen INC. | $59.73 | 2020-2025 | Repatha, Otezla, Otezla |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $47.82 | 2022-2024 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.98 | 2020-2025 | Jardiance |
| Glaxosmithkline, LLC. | $34.39 | 2022 | |
| Sanofi-Aventis U.S. LLC | $31.39 | 2021-2023 | |
| Amarin Pharma, INC. | $27.24 | 2019-2020 | |
| Organon LLC | $27.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $26.47 | 2020 | |
| Upsher-Smith Laboratories LLC | $25.11 | 2019 | |
| Eisai INC. | $21.00 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.87 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $17.77 | 2022 | |
| Gilead Sciences, INC. | $17.58 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.73 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.63 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.23 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.08 | 2024 | Caplyta |
| Abbott Laboratories | $14.78 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.20 | 2020 | |
| Allergan, INC. | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.